ADDING ADDITIONAL FUNDS FOR OPTION PERIOD 1 FOR TOPMED CENTRALIZED OMICS RESOURCE (CORE) YEAR 5
ADDING ADDITIONAL FUNDS FOR OPTION PERIOD 1 FOR TOPMED CENTRALIZED OMICS RESOURCE (CORE) YEAR 5
批准号:
10510158
负责人:
CATHERINE REEVES
金额:
$564.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-28 至 2022-09-27
中文摘要
针对至少1,000个样本的转录组RNAseq的NHLBI RFP,我们建议使用Illumina TruSeq单链HT mRNA试剂盒对这些样本进行测序,并使用Illumina NovaSeq上的成对末端2x100个碱基阅读器对Illumina NovaSeq上的文库进行测序,每个血液来源样本的映射读数为75M,每个组织来源的或珠蛋白耗竭的血液来源样本的映射读数为50M,目标是总样本数为17,100个。下面描述了这一过程的细节,以及支持我们方法的数据。
英文摘要
In response to the NHLBI RFP for Transcriptome RNAseq of a minimum of 1,000 samples, we are proposing to profile these samples using the Illumina TruSeq Stranded HT mRNA kit for library preparation, and to sequence the libraries on the Illumina NovaSeq using paired-end 2x100bp reads with eight-base unique dual index barcodes at a minimum depth of 75M mapped reads per blood derived samples and 50M mapped reads per tissue derived or globin-depleted blood derived samples, delivered as CRAM, with a goal of 17,100 samples total. The details of this process are described below, together with data supporting our approach.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金